Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Façade for prognostic markers.

Atallah, Bassam; El Nekidy, Wasim; Mallah, Saad I; Cherfan, Antoine; AbdelWareth, Laila; Mallat, Jihad; Hamed, Fadi

Atallah, Bassam; El Nekidy, Wasim; Mallah, Saad I; Cherfan, Antoine; AbdelWareth, Laila; Mallat, Jihad; Hamed, Fadi.

Afiliação

Atallah B; Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi, United Arab Emirates.
El Nekidy W; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH USA.
Mallah SI; Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi, United Arab Emirates.
Cherfan A; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH USA.
AbdelWareth L; School of Medicine, Royal College of Surgeons in Ireland-Bahrain, Al Sayh, Bahrain.
Mallat J; Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi, United Arab Emirates.
Hamed F; Department of Clinical Pathology, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi, United Arab Emirates.

Thromb J ; 18: 22, 2020.

Article em En | MEDLINE | ID: mdl-32922212

Palavras-chave

COVID-19; D-dimers; Prognostic markers; Thrombosis; Tocilizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Thromb J Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Emirados Árabes Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google